Education
About Us
Working with TipRanks
Follow Us
Hikma Pharma (HKMPY)
:HKMPY
Earnings Data
Report Date
Feb 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
1.19Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong revenue growth and strategic advancements offset by some declines in operating profit and cash flow. There are clear strategies in place for future growth, but immediate challenges such as FX headwinds and margin pressures were noted.Company Guidance -
Q4 2025
Strong Revenue Growth
Hikma delivered a 6% revenue growth driven by robust volumes across all business segments and regions, with recent launches and the benefit of the fully integrated Xellia acquisition contributing to growth.
Injectables Segment Success
Injectables segment saw 12% core revenue growth year-on-year, with strong performances in Europe (26% growth) and MENA (16% growth).
Strategic Partnerships and Pipeline Expansion
Hikma signed new strategic partnerships and made strides in strengthening its pipeline and enhancing manufacturing capabilities.
Branded Business Growth
The Branded business achieved 4% top-line growth and 3% operating profit growth, with 14 product launches and 36 regulatory filings in the first half of 2025.
Low Leverage Ratio
The company maintains a healthy balance sheet with a leverage ratio of 1.7x net debt to core EBITDA.
Positive Market Developments in Rx Division
Hikma Rx saw solid performance with good growth from inhalation products, launching 3 new products, and submitting 3 new regulatory filings.
HKMPY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HKMPY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $50.23 | $46.91 | -6.61% |
Feb 26, 2025 | $57.06 | $53.72 | -5.85% |
Aug 08, 2024 | $45.44 | $49.17 | +8.21% |
Feb 22, 2024 | $48.00 | $50.09 | +4.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hikma Pharma (HKMPY) report earnings?
Hikma Pharma (HKMPY) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is Hikma Pharma (HKMPY) earnings time?
Hikma Pharma (HKMPY) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HKMPY EPS forecast?
Currently, no data Available